MedImmune Ventures, a wholly-owned venture capital fund within the AstraZeneca Group, invests in private companies which develop small and large molecules, vaccines, pharmaceutical technologies and platforms. We invest in medical device, diagnostic, imaging and healthcare IT companies which pertain to the discovery, development and commercialization of pharmaceutical products.
Our therapeutic scope is broad, including cardiology, gastroenterology, neuroscience, oncology, pulmonology, infectious disease, inflammation and metabolism, among others. While MedImmune Ventures team members have been based in North America, we consider investments anywhere in the world where we have strong local relationships.
Stage-wise, MedImmune Ventures invests in companies with early to late stage products and technologies, in early (e.g. seed) to late (e.g. mezzanine) rounds of financing. With $400M in capital commitments, MedImmune Ventures has invested in over 30 companies since 2002.